Articles tagged with Rheumatoid Arthritis
A study found that people with rheumatoid arthritis are less protected by the hepatitis B vaccine, highlighting increased risk of infection despite vaccination. The vaccine's efficacy was lower in RA patients compared to those without the condition.
Fatigue remains a debilitating problem for RA patients, with healthcare professionals often failing to measure it. New guidelines recommend validated fatigue measurements to improve patient outcomes. In contrast, treatment aimed at achieving disease remission is unlikely to be effective in addressing fatigue.
Early RA patients exhibit cardiomyopathy, reduced vascular function, and increased cardiovascular mortality. Cardiac MRI revealed aortic stiffness, left ventricular volumes, and geometry changes indicative of cardiac abnormalities.
A systematic review of 15 randomized controlled trials found that biologics significantly reduce accumulated missed workdays and improve work productivity among patients with rheumatic diseases. This suggests a potential economic benefit to treating these conditions.
The tREACH trial found that combination DMARDs (methotrexate, sulfasalazine, and hydroxychloroquine) improve measures of disease activity and functional ability in patients with early rheumatoid arthritis. This suggests an earlier decrease in disease severity and improvements in functional ability compared to monotherapy.
A study presented at EULAR 2015 found that ultrasound diagnosis of tenosynovitis was superior to clinical symptoms in predicting early RA. This procedure has the potential to improve clinical outcomes by identifying the need for treatment before symptom onset.
A study found that RA patients with moderate disease activity are at risk of needing joint surgery, challenging existing treatment guidelines. The findings suggest updating disease activity cut-off points to allow moderate-disease-activity patients to receive biologics.
A world-first vaccine-style therapeutic approach has demonstrated safety and effectiveness in suppressing the immune response in a phase one clinical trial for rheumatoid arthritis. The treatment targets high-risk genes and antibodies associated with the disease.,
A recent UK study found that 40% of rheumatoid arthritis patients scored low on an adherence questionnaire, indicating inconsistent medication use. The research highlights the need for healthcare professionals to better inform patients about the importance of taking drugs as prescribed.
A team of researchers from Montana State University has identified a new chemical compound called IQ-1S that shows promise in treating rheumatoid arthritis. The study found that IQ-1S significantly reduced the severity of collagen-induced arthritis and inhibited the destruction of cartilage and bone.
A new class of medications could prevent joint damage and provide relief to patients who don't respond to available treatments. The novel drug target, RPTPσ, inhibits the aggressive invasion of synoviocytes into joint cartilage by acting as an inhibitory signal.
Research suggests that 1 in 4 patients with rheumatoid arthritis and no symptoms have coronary heart disease, increasing their risk of cardiovascular death. The study found that persistence of systemic inflammation may cause accelerated atherosclerosis process in rheumatoid arthritis patients.
Patients with rheumatoid arthritis who experience weight loss are at higher risk of early death. The study's findings suggest a potential link between unintentional weight loss and mortality in this patient population.
A new study has discovered specific genetic variants associated with higher risks of increased disease severity in rheumatoid arthritis. Certain amino acid positions in the HLA-DRB1 gene were found to be strong predictors of radiological damage, enabling early identification and potential treatment optimization.
A recent study found that patients with rheumatoid arthritis face high initial copayments and then fall into a coverage gap, where they pay 45% of drug costs. This financial burden can be substantial, with some patients paying over $2,700 annually before receiving relief from catastrophic coverage.
A team from the University of Birmingham identified a novel pathway regulating immune cell movement during inflammation. The study shows that beneficial effects are lost in diseases such as diabetes and arthritis, and during normal aging. This discovery may lead to new therapies targeting this pathway.
Researchers at the University of Warwick have identified a biomarker linked to both rheumatoid and osteoarthritis, potentially leading to an early diagnosis of OA and RA. The development of a blood test using this biomarker could help patients receive treatment several years before physical symptoms appear.
Researchers found increased pocket depth and clinical attachment loss in patients with rheumatoid arthritis, highlighting the link between gum disease and joint inflammation. The study also identified Porphyromonas gingivalis antibodies as biomarkers for identifying patients who may benefit from periodontal treatment.
A study led by Tokyo Medical University researcher Toshihiro Nakajima found that an anti-inflammatory drug can counteract obesity in mice by regulating mitochondrial biogenesis and fatty acid breakdown. The drug, LS-102, inhibits the Synoviolin gene, leading to increased energy control pathways.
Researchers identified super-enhancers in T cells as key to regulating the immune system, which may lead to new treatments for autoimmune disorders such as rheumatoid arthritis. The study found that these enhancers control genes involved in T cell function and activity.
A study of almost 6500 people found that recent gut and urinary tract infections were associated with a significantly lowered risk of developing rheumatoid arthritis. Infections within the past two years reduced the risk by 29%, 22% and 20% respectively.
Researchers found that blood tests can produce similar results for patients with Chikungunya virus and those with rheumatoid arthritis, highlighting the need for diagnostic tools. Detailed travel histories are crucial to distinguish between the two conditions.
A study at Hospital for Special Surgery found that a support group addressing the psychological and educational needs of people recently diagnosed with rheumatoid arthritis has a strong positive impact on their lives. The program improved patients' ability to manage their disease, connect with others, and cope with emotional challenges.
New clinical data show Vectra DA is a strong predictor of radiographic progression over two years compared to other tests used to assess risk of joint damage. The study found that among patients with low CRP, high Vectra DA scores were associated with increased risk of radiographic progression.
Researchers found that patients with underweight or overweight/obese BMIs were less likely to achieve sustained remission in early rheumatoid arthritis. The study also identified other contributing factors, such as smoking and response to treatment, that can impact patient outcomes.
A blood test shows promise as a marker to predict which rheumatoid arthritis patients will benefit from biologic medications, sparing them unnecessary side effects. The protein type 1 interferon appears to serve as a valid marker to tell whether individual patients will respond to biologics or need alternative treatments.
Research found that babies born to mothers with rheumatoid arthritis have lower fetal growth and are more likely to be born prematurely. Studies show a 1.5 times higher risk of preterm birth in children exposed to maternal or preclinical RA compared to those without exposure.
Crescendo Bioscience will showcase new clinical data on Vectra DA at the 2014 ACR Annual Meeting, highlighting its value in assessing RA disease activity and predicting patient risk of joint damage. The company will present two oral presentations and four poster presentations.
A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects. The COBRA Slim strategy, which calls for the least amount of medication, had half as many side effects as the two other strategies and was just as effective.
Researchers at Hospital for Special Surgery have discovered a novel cell signaling pathway contributing to bone destruction in rheumatoid arthritis. The study suggests that RBP-J protein controls excessive bone erosion through a newly identified signaling pathway.
Researchers found that women with children carrying high-risk HLA genes are more likely to develop rheumatoid arthritis. The study suggests a possible link between fetal microchimerism and the disease, which may be mediated by interactions between immune system proteins encoded by these genes.
The National Institutes of Health has established an Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus (AMP RA/Lupus) Network to transform the current model for identifying promising biological targets for new drugs and diagnostics. The network will analyze interplay among biological pathways, including at the single...
Researchers found cartilage plays an active role in rheumatoid arthritis destruction and remodelling, contradicting the long-held assumption that it's a passive victim of inflammation. Cartilage produces enzymes driving tissue degradation and releases signaling molecules triggering an autoimmune response.
A new study found that high sodium intake in smokers doubles the risk of developing rheumatoid arthritis. The study suggests an additive interaction between sodium and smoking as a risk factor for RA.
A team of researchers at the University of Illinois Chicago has identified a single receptor, TLR5, that triggers inflammation and bone degradation in rheumatoid arthritis. Blocking this receptor may provide a new therapeutic target to interrupt the disease's vicious cycle.
A new study found that 27% of rheumatoid arthritis patients in the UK failed to take their expensive anti-TNF therapy as prescribed. Non-adherence to medication reduced its effectiveness and worsened disease outcomes, highlighting a significant concern for healthcare resources.
A study by Wayne State University researchers found that cognitive-behavioral coping skills training significantly improved RA patients' pain and mood for at least a year. In contrast, written emotional disclosure had only short-term benefits on joints and functioning. The combination of both therapies showed no unique benefits.
A new fusion molecule has been developed to treat rheumatoid arthritis in mice, with promising results showing the animals' symptoms disappear completely. The therapy targets specific immune messengers and reduces side effects by concentrating the active substance at the site of disease, offering a potential long-term cure.
Rheumatoid arthritis is considered a syndrome rather than a single disease, and blocking inflammasomes may be an effective therapeutic target. Researchers have developed a mouse model that demonstrates the role of inflammasomes in RA and show promise for new treatments.
Amino acids at positions 11, 71 and 74 on the HLA-DRB1 gene identify RA patients at risk of joint damage and early death. The findings suggest that genotyping can predict disease outcomes in rheumatoid arthritis patients.
Researchers have identified a potential biomarker of response to etanercept and adalimumab in patients with rheumatoid arthritis (RA) through DNA methylation analysis. The study found that epigenetic changes, such as DNA methylation, may provide potential biomarkers of response to anti-TNFs.
Researchers at Benaroya Research Institute used cutting-edge tetramer technology to find T cells driving rheumatoid arthritis. The study demonstrates that these cells have unique markers and change over time in patients with RA.
A recent EULAR study found that obese patients with rheumatoid arthritis (RA) have higher disease activity scores than non-obese patients, irrespective of their disease stage. This suggests that treatment to target protocols may result in obese patients being treated more aggressively than non-obese patients.
New studies have found that daily intake of monounsaturated fatty acids is an independent predictor of remission in patients with RA, while excessive cholesterol levels increase cartilage damage in OA. The Mediterranean diet has been shown to reduce inflammatory activity and improve function in RA patients.
An international team created a heart disease risk calculator for rheumatoid arthritis patients, identifying those at high risk more effectively than standard tools. The calculator incorporates disease characteristics into cardiovascular risk assessment, shedding light on how to better gauge heart health in inflammatory diseases.
Vectra DA data demonstrates clinical utility in assessing risk of future joint damage, with high scores associated with radiographic progression. The test may help identify patients at higher or lower risks for radiographic progression while receiving antirheumatic therapy.
Researchers discovered that CCL28 and its receptor are key players in angiogenesis, a hallmark of rheumatoid arthritis. This finding provides strong evidence for the binding of CCL28 to joint-lining cells as necessary for blood vessel formation.
Researchers from Scripps Research Institute will develop new technology to diagnose three diseases using a unique group of enzymes known as protein arginine deiminases (PAD). PADs have been linked to inflammatory diseases like rheumatoid arthritis, cancer, and Alzheimer's disease.
A traditional Chinese herbal remedy, Tripterygium wilfordii Hook F, has been shown to be as effective as methotrexate in treating rheumatoid arthritis. Combining the herbal remedy with methotrexate resulted in improved outcomes for patients, including significant reductions in disease activity and remission rates.
Researchers found that rheumatoid arthritis patients have a 1 in 4 chance of developing chronic kidney disease over a 20-year period, compared to the general population's 1-in-5 risk. Patients should work to keep blood pressure under control and avoid medications damaging to the kidneys.
Researchers have identified genetic variants associated with two forms of rheumatoid arthritis, sero-positive and sero-negative. This breakthrough could lead to better diagnosis and targeted treatment for patients.
Researchers from Hospital for Special Surgery found that same-day bilateral knee replacement surgery is safe for select patients with rheumatoid arthritis. The study analyzed hospital data from 240 RA patients and 3,680 OA patients and found no higher complication rate in the RA group.
Research reveals that levels of depression and anxiety among people with severe rheumatoid arthritis are significantly higher than previously reported. The study suggests that routine screening for depression is crucial, as untreated depression can impact treatment outcomes. The researchers propose modifying the current disease activit...
A Mayo Clinic study found that nearly all patients with intact rotator cuffs experience improved function and pain relief after shoulder replacement surgery. The procedure improves range of motion and reduces pain in nearly all cases, especially for those with rheumatoid arthritis.
A new study of over 7,000 older Chinese women found that breastfeeding was associated with a lower risk of rheumatoid arthritis (RA), with women who breastfed being around half as likely to develop the condition. The study also found a statistically significant trend of decreasing RA risk with increasing duration of breastfeeding.
A large international study has identified new genetic loci associated with rheumatoid arthritis, shedding light on the disease's biology. The research demonstrates that integrating genetic data with existing biological information can lead to the discovery of potential drugs for treating the condition.
An international group of investigators has discovered new genetic variations and cell types involved in inherited susceptibility to rheumatoid arthritis. The study provides a definitive list of major common genetic variation involved in the disease, leading to potential new therapies.
A large longitudinal study found that postmenopausal women with RA and anti-CCP antibodies had a significantly higher mortality rate compared to those without these antibodies. The main cause of death was cardiovascular disease, including coronary heart disease and stroke.
Researchers at Scripps Florida Institute developed a compound that dramatically reduces joint inflammation in animal models of rheumatoid arthritis. The study showed the compound, SR2211, blocked symptoms and bone erosion in mice within eight to ten days of treatment.
Researchers found that anxiety, depressed mood, and physical disability among RA patients decreased by half over the past two decades. Improved treatment options, including early therapy intervention and biologics, have led to reduced disease activity and better daily living for these patients.